相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Sarah Fischer et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
Michiel Bronswijk et al.
INFLAMMATORY BOWEL DISEASES (2020)
Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar
Desmond P. Kidd et al.
NEUROLOGY (2020)
Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts
Alain Calender et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(R)to Remsima(R)? An Observational Study
Laixi Xue et al.
FRONTIERS IN MEDICINE (2020)
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Roy Fleischmann et al.
RHEUMATOLOGY AND THERAPY (2020)
Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment
Quentin Riller et al.
JOURNAL OF NEUROLOGY (2019)
New advances in the management of pulmonary sarcoidosis
Daniel A. Culver et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review
Georgios Bakalos et al.
CLINICAL THERAPEUTICS (2019)
The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis
Mohammed I. Aladul et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2019)
Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis
Milou C. Schimmelpennink et al.
RESPIRATORY MEDICINE (2018)
The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
F. Magro et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme
Violeta Razanskaite et al.
JOURNAL OF CROHNS & COLITIS (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
Changsoo Lee et al.
MABS (2017)
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
Seokkyun Kim et al.
MABS (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis
Adriane D. M. Vorselaars et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment
Henricus N. A. J. van Rijswijk et al.
EXPERT OPINION ON ORPHAN DRUGS (2013)
Long-Term Treatment with Infliximab in Patients with Sarcoidosis
Katrin E. Hostettler et al.
RESPIRATION (2012)
Cytokine modulators in the treatment of sarcoidosis
E. Bargagli et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
Robert P. Baughman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
分享论文
